FSTL1 and cirrhosis of liver: In summary, our findings reveal that FSTL1, which promotes early macrophage recruitment to facilitate subsequent effective macrophage accumulation during stem cell therapy, could potentially serve as a predictive biomarker of the response to stem cell therapy in patients with liver cirrhosis.